ST11 KPC-2-Producing Klebsiella pneumoniae Isolated from Patient with Acute Myelocytic Leukemia

Figures & data

Figure 1 (A) Clinical diagnosis and treatment of patients. (B) Changes in infection during hospitalization. HAA, homoharringtonine combined aclarubicin and cytarabine; IA, idarubicin combined with cytarabine; Ara-c, cytarabine; FACT, functional assessment of cancer treatment; HSCT, hematopoietic stem cell transplantation.

Table 1 The Isolation Time and Sources of Eight ST11-CR-HvKP Isolates

Strains	Isolation Time	Source
Jinyinhai1	2022.04.09	Stool
22A008038A	2022.04.10	Blood
22A008014A	2022.04.10	Blood
22A008081B	2022.04.11	Blood
22R000695R	2022.04.12	Stool
Jinyinhai2	2022.04.12	Blood
22A008202A	2022.04.12	Blood
22R000724R	2022.04.14	Stool

Table 2 Antimicrobial Susceptibilities of Eight ST11-CR-HvKP Isolates

	Jinyinhai1	Jinyinhai2	22A008038A	22A008014A	22A008081B	22A008202A	22R000695R	22R000724R
Ticarcillin/ Clavulanic Acid	≥128 / R	≥128 / R	≥128 / R	≥128 / R	≥128 / R	≥128 / R	≥128 / R	≥128 / R
Piperacillin/ Tazobactam	≥128 / R	≥128 / R	≥128 / R	≥128 / R	≥128 / R	≥128 / R	≥128 / R	≥128 / R
Ceftazidime	≥64 / R	≥64 / R	≥64 / R	≥64 / R	≥64 / R	≥64 / R	≥64 / R	≥64 / R
Cefoperazone/ Sulbactam	≥64 / R	≥64 / R	≥64 / R	≥64 / R	≥64 / R	≥64 / R	≥64 / R	≥64 / R
Cefepime	≥32 / R	≥32 / R	≥32 / R	≥32 / R	≥32 / R	≥32 / R	≥32 / R	≥32 / R
Aztreonam	≥64 / R	≥64 / R	≥64 / R	≥64 / R	≥64 / R	≥64 / R	≥64 / R	≥64 / R
Imipenem	≥16 / R	≥16 / R	≥16 / R	≥16 / R	≥16 / R	≥16 / R	≥16 / R	≥16 / R
Meropenem	≥16 / R	≥16 / R	≥16 / R	≥16 / R	≥16 / R	≥16 / R	≥16 / R	≥16 / R
Amikacin	≥64 / R	≥64 / R	≥64 / R	≥64 / R	≥64 / R	≥64 / R	≥64 / R	≥64 / R
Tobramycin	≥16 / R	≥16 / R	≥16 / R	≥16 / R	≥16 / R	≥16 / R	≥16 / R	≥16 / R
Ciprofloxacin	≥4 / R	≥4 / R	≥4 / R	≥4 / R	≥4 / R	≥4 / R	≥4 / R	≥4 / R
Levofloxacin	≥8 / R	≥8 / R	≥8 / R	≥8 / R	≥8 / R	≥8 / R	≥8 / R	≥8 / R
Doxycycline	≥16 / R	≥16 / R	≥16 / R	≥16 / R	≥16 / R	≥16 / R	≥16 / R	≥16 / R
Minocycline	≥16 / R	≥16 / R	≥16 / R	≥16 / R	≥16 / R	≥16 / R	≥16 / R	≥16 / R
Tigecycline	2 / S	2 / S	2 / S	2 / S	2 / S	2 / S	≥8 / R	2 / S
Colistin	≤0.5 / S	≤0.5 / S	≤0.5 / S	≤0.5 / S	≤0.5 / S	≤0.5 / S	≤0.5 / S	≤0.5 / S
Trimethoprim/ Sulfamethoxazole	≥320 / R	≥320 / R	≥320 / R	≥320 / R	≥320 / R	≥320 / R	≥320 / R	≥320 / R

Figure 2 A comparative genome analysis of eight ST11-CR-HvKP isolates based on core genome SNPs. Isolates with zero cgSNP differences were marked by the same color. The collection dates, isolation sources, and antimicrobial resistance genes are shown. Blue indicates that the isolate carries such genes and colorless means that the genes are not present.

Table 3 The Biofilm-Forming Ability of Eight ST11-CR-HvKP Isolates

Strain	OD600	Biofilm Formation Ability
Jinyinhai1	0.18	Weakly to moderately adherent
Jinyinhai2	0.15
22A008038A	0.17
22A008014A	0.18
22A008081B	0.20
22A008202A	0.17
22R000695R	0.18
22R000724R	0.19
Control	0.09	–

Figure 3 The genetic features of eight ST11-CR-HvKP isolates. (A) Plasmid profiles of eight ST11-CR-HvKP. (B) Genetic context of bla_KPC-2 genes in this study. (C) Comparative analysis of plasmid pJinyinhai1_KPC detected in K. pneumoniae Jinyinhai1.